Teagarden Alicia M, Skiles Jodi L, Beardsley Andrew L, Hobson Michael J, Moser Elizabeth A S, Renbarger Jamie L, Rowan Courtney M
Section of Critical Care, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Section of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Pediatr Transplant. 2017 Sep;21(6). doi: 10.1111/petr.13016. Epub 2017 Jul 2.
Poor nutritional status in HCT patients is a negative prognostic factor. There are no pediatric studies evaluating albumin levels prior to HCT and need for critical care interventions. We hypothesized that pediatric patients with low albumin levels, routinely measured 30 days (±10 days) prior to allogeneic HCT, have a higher risk of critical care interventions in the post-transplant period. We performed a 5-year retrospective study of pediatric patients who underwent allogeneic HCT for any indication. Patients were categorized based on albumin level. Hypoalbuminemia was defined as <3.1 g/dL. A total of 73 patients were included, with a median age of 7.4 years (IQR 3.3, 13.2). Patients with hypoalbuminemia had higher needs for critical care interventions including non-invasive ventilation (44% vs 8%, P=.01), mechanical ventilation (67% vs 17%, P<.01), and vasoactive therapy (56% vs 16%, P=.01). Patients with hypoalbuminemia also had a higher 6-month mortality (56% vs 17%, P=.02). Our data demonstrate that children undergoing allogeneic HCT with hypoalbuminemia in the pretransplant period are more likely to require critical care interventions and have higher 6-month mortality. These findings identify an at-risk population in which nutritional improvements may be instituted prior to HCT in hopes of improving outcomes.
造血干细胞移植(HCT)患者的营养状况不佳是一个负面预后因素。目前尚无关于评估HCT前白蛋白水平及重症监护干预需求的儿科研究。我们推测,在异基因HCT前30天(±10天)常规测量白蛋白水平较低的儿科患者,在移植后时期需要重症监护干预的风险更高。我们对因任何适应症接受异基因HCT的儿科患者进行了一项为期5年的回顾性研究。根据白蛋白水平对患者进行分类。低白蛋白血症定义为<3.1 g/dL。共纳入73例患者,中位年龄为7.4岁(四分位间距3.3,13.2)。低白蛋白血症患者对重症监护干预的需求更高,包括无创通气(44%对8%,P=0.01)、机械通气(67%对17%,P<0.01)和血管活性治疗(56%对16%,P=0.01)。低白蛋白血症患者的6个月死亡率也更高(56%对17%,P=0.02)。我们的数据表明,移植前患有低白蛋白血症的接受异基因HCT的儿童更有可能需要重症监护干预,且6个月死亡率更高。这些发现确定了一个高危人群,在HCT前可改善其营养状况,以期改善预后。